Q Biomed inc   (QBIO)
Other Ticker:  
Price: $0.0075 $0.00 0.000%
Day's High: $0.0075 Week Perf: -21.05 %
Day's Low: $ 0.01 30 Day Perf: -25 %
Volume (M): 2,157 52 Wk High: $ 0.48
Volume (M$): $ 16 52 Wk Avg: $0.10
Open: $0.01 52 Wk Low: $0.01

 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 45
 Employees 8
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -7
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Q Biomed Inc

We are a biotechnology acceleration and development company focused on acquiring and in-licensing pre-clinical, clinical-stage and approved life sciences therapeutic products. Currently, we have a portfolio of four therapeutic products, including an FDA approved product, Strontium 89, a radiopharmaceutical for metastatic cancer bone pain, and three development stage products: QBM-001 for rare pediatric non-verbal autism spectrum disorder, Uttroside-B for liver cancer, and MAN 01 for glaucoma. We aim to maximize risk-adjusted returns by focusing on multiple assets throughout the discovery and development cycle. We expect to benefit from early positioning in illiquid and/or less well known privately-held assets, thereby enabling us to capitalize on valuation growth as these assets move forward in their development.

Our goal is to become a leading biotechnology acceleration and development company with a diversified portfolio of therapeutic products commercially available and in development. To achieve this goal, we are executing on the following strategy:

Strategically collaborate or in- and out-license select programs.
We seek to collaborate or in- and out-license certain potentially therapeutic candidate products to biotechnology or pharmaceutical companies for preclinical and clinical development and commercialization.

Highly leverage external talent and resources.
We plan to maintain and further build our team which is skilled in evaluating technologies for development and product development towards commercialization. By partnering with industry specific experts, we are able to identify undervalued assets that we can fund and assist in enhancing inherent value. We plan to continue to rely on the extensive experience of our management team to execute on our objectives.

Evaluate commercialization and monetization strategies on a product-by-product basis in order to maximize the value of our product candidates or future potential products.

As we move our drug candidates through development toward regulatory approval, we will evaluate several options for each drug candidate’s commercialization or monetization strategy. These options include building our own internal sales force; entering into a joint marketing partnership with another pharmaceutical or biotechnology company, whereby we jointly sell and market the product; and out-licensing any product that we develop by ourselves or jointly with another party, whereby another pharmaceutical or biotechnology company sells and markets such product and pays us a royalty on sales. Our decision will be made separately for each product and will be based on a number of factors including capital necessary to execute on each option, size of the market to be addressed and terms of potential offers from other pharmaceutical and biotechnology companies. It is too early for us to know which of these options we will pursue for our drug candidates, assuming their successful development.

Acquire commercially or near-commercially ready products and build out the current market for such.
In addition to acquiring pre-clinical products, in assembling a diversified portfolio of healthcare assets, we plan on acquiring assets that are either FDA approved or are reasonably expected to be FDA approved within 12 months of our acquiring them. We anticipate hiring a contract sales organization to assume the bulk of the sales and distribution efforts related to any such product.

   Company Address: c/o Ortoli Rosenstadt LLP New York 10017 NY
   Company Phone Number: 588-0022   Stock Exchange / Ticker: QBIO
   QBIO is expected to report next financial results on February 27, 2023.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Standex International Corp

A soft Sales improvement at SXI in the most recent fiscal period

For the October to December 31 2022 period SXI profit per share surged by 36.29 % of $1.69 per share compare to $1.24 a year before and EPS surged by 10.46 % from $1.53 per share from the prior quarter.

Sales grew gently by 1.12 % to $187.79 millions from $185.71 millions in the same quarter a year before and sequentially Sales surged by 3.981 % from $180.60 millions.

Graniteshares Platinum Trust

In the October to December 31 2022 three months PLTM had turn a round to surplus by displaying EPS at $1.98 per share, opposite of $-0.03 per share a year before financial reporting period, In the prior financial reporting period The company realized $-0.45 per share.

Graniteshares Gold Trust

Graniteshares Gold Trust reported that Sales has tumbled, during the most recent fiscal period

For the second quarter of 2022 BAR income per share increased by 75.95 % of $1.39 per share compare to $0.79 a year before and EPS turned positive from $-1.48 per share from the preceding quarter.

Sales went down sharply by -84.747 % to $3.59 millions from $23.52 millions in the comparable quarter a year before and sequentially Sales Tumbled by -49.895 % from $7.16 millions.

Kange Corp

Kange Corp added some great scenario for the shareholders, presenting a significant improvement in fourth quarter of 2022 financial report with operating profit of $0.010331 millions

The shareholders haven't expected any changes at the top-line throughout the the September to November 30 2022 reporting cycle at the Kange Corp . However, they pay near attention to the Computer processing and cloud services company's operating profit that has been at $0.010331 millions, during the same period.

Ubiquiti Inc

Income grew by 12.05 % at the Ubiquiti Inc all along the financial time-frame ending December 31 2022

In the fiscal span closing Dec 31 2022 UI had Sales of $493.57 millions and earnings per share of $1.86. Sales were up by 14.368 % year on year and net profit per share grew by 12.05 %.


Q Biomed Inc 's Segments
• View Complete Report


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production


Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales


Event Calendar

RGS's Profile

Stock Price

RGS's Financials

Business Description


Charts & Quotes

RGS's News


RGS's Competitors

Customers & Markets

Economic Indicators

RGS's Growth

Company Segments


Stock Performance

Growth Rates




Financial Strength


Largest Companies

Management Effectivness


At a Glance


Growth Rates



Financial Strength


At a Glance



Sectors & Industries




At a Glance








About us


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071